Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $810 | Backorder | |
1 mg | $5,400 | Backorder |
Description | Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-His-Avi |
Accession Number | AAA59600.1(HLA-A*24:02)&P61769(B2M)&IMPKAGLLI |
Synonyms | CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402,HLA-A*24:02,Melanoma-associated antigen 3 |
Construction | Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and IMPKAGLLI peptide |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.